Antibody-drug conjugates as drug carrier systems for bioactive agents
| Autor: | Amna Parveen, Kanwal Rehman, Muhammad Ibrahim, Muhammad Sajid Hamid Akash |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Drug Polymers and Plastics General Chemical Engineering media_common.quotation_subject Pharmacology Systemic circulation Analytical Chemistry 03 medical and health sciences 0302 clinical medicine Therapeutic index Hardware_INTEGRATEDCIRCUITS Medicine Hardware_ARITHMETICANDLOGICSTRUCTURES Hardware_REGISTER-TRANSFER-LEVELIMPLEMENTATION media_common Therapeutic strategy biology business.industry body regions ComputingMethodologies_PATTERNRECOGNITION 030104 developmental biology Stringent factor 030220 oncology & carcinogenesis biology.protein Cancer research Antibody Drug carrier business |
| Zdroj: | International Journal of Polymeric Materials and Polymeric Biomaterials. 65:1-10 |
| ISSN: | 1563-535X 0091-4037 |
| DOI: | 10.1080/00914037.2015.1038818 |
| Popis: | Conventional therapeutic strategies for the treatment of various types of cancers and tumors are known to have poor therapeutic indexes, lack of specificity, and potential cytotoxic effects on normal healthy tissues. Antibody-drug conjugates (ADCs) are considered as novel therapeutic strategy for the treatment of various diseases especially cancer. ADCs reduce the chances of systemic cytotoxicity and, ultimately, increase the therapeutic index of conjugated drug. ADCs are stable in systemic circulation, but for the success of ADCs, all the components of ADC should function in a flawless manner. Despite of these components of ADCs, target selection is another stringent factor that also needs equal consideration during the development of ADC. The authors briefly discuss the key requirements of ADCs that seek further advancements for the success of ADCs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|